Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 2
globenewswire.comOlema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancerglobenewswire.comMay 26
globenewswire.comOlema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meetingglobenewswire.comMay 21
globenewswire.comOlema Oncology to Participate in Upcoming Investor Conferencesglobenewswire.comMay 19
globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comMay 4